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Introduction
In 2010 in Italy, there were 175,046 cancer deaths, with total
mortality rates, respectively for men and women, of 138 and
83/100,000 [1]. Total cancer mortality in Italy has been declining since
the 1980s in men and earlier in women [1], similarly to most European
countries [2] and the United States [3]. However, some rising trends
have also been observed, notably for female lung cancer and pancreatic
cancer in both sexes [1]. Although the incidence of pancreatic cancer is
relative low compared to other tumor types such as breast, lung and
prostate cancer, in pancreatic cancer the mortality is almost equal to
the incidence level, with 41,780 and 40,560 deaths predicted in Europe
and USA respectively [2,4]. For this reason, PDA is the 4th leading
cause of cancer deaths in the Western Countries [1,2,4]. Despite the
efforts of clinicians and scientists, pancreatic cancer has the worst
prognosis of all major malignancies, with a 5-year survival rate of 8%
[4].
Pancreatic ductal adenocarcinomas (PDA), originate from the
exocrine pancreas, account for 95% of pancreatic cancers and is
characterized by rapid progression, invasiveness and resistance to both
radiation and chemotherapy [5]. Therefore, surgery provides the only
possibility for cure, but most patients present metastatic PDA upon
initial diagnosis, and less than 20% of patients are suitable candidates
at the time of diagnosis and 5-years survival of completely resected
patients is only up to 25% [5]. The major hurdle for PDA is the lack of
markers for early diagnosis, along with few efficacious therapies.
Alpha-Enolase (Eno1) and Anti-Eno1 Antibody-Based
Immunotherapy
In recent years, targeted therapies have been tested for treating
metastatic pancreatic cancer, for example Erlotinib, an inhibitor of the
epidermal growth factor receptor (EGFR) (ClinicalTrials.gov number
NCT01608841), is a successful example of how using an antibody, in
combination with gemcitabine-based chemotherapy, is effective in
improving overall and progression-free survival, as well as response
rates in metastatic PDA patients [6].
Immunotherapy, by both passive and active approaches, can be
considered as a kind of “targeted therapy” in terms of activating the
immune system against a specific target, or nullifying it through an
antibody. We have previously identified novel PDA-associated antigens
by detecting autoantibodies in the sera of PDA patients, which can be
considered as “spies” of the activation of the immune system [7]. Some
of these antigens have been characterized as suitable therapeutic
targets, such as α-Enolase (ENO1) [8]. ENO1 is a multi-functional
protein, acting as both a glycolytic enzyme and a plasminogen receptor
expressed on the cell surface of tumor cells, thus playing a critical role
in metastasis and spreading [9]. As glycolytic enzyme is ubiquitously
expressed in almost normal tissues (see website www.proteinatlas.org)
including liver, brain, spleen, adipose tissue, kidney [10], reproductive
tract [11] and pancreas [8]. By promoting plasminogen activation into
plasmin, a serine-protease involved in extracellular matrix
degradation, ENO1 favors cell invasion and metastasis (Figure1 upper
panel) [9]. The plasminogen system is involved in tumor growth,
invasion and metastasis [12]. Several proteins of this system have been
demonstrated to have a clinical value as diagnostic and prognostic
markers in cancer. In particular, overexpression of plasminogen
receptors has been associated with poor prognosis, shorter survival
and resistance to chemotherapy [12].
We first characterized ENO1 as a plasminogen receptor; it is
expressed on the surface of human PDA cells lines and at higher levels
in metastatic cell lines, whereas it is absent or expressed at lower levels
in primary tumor-derived cell lines [13]. Ex vivo analysis of a liver
metastasis-derived cell line (PANC-1/M) revealed an increased cell
surface expression of ENO1 compared to the parental cell line
(PANC-1/P) from the primary tumor. This observation suggests that
spreading and invasion of PDA cells is strictly related to the high cell
surface expression of ENO1, which, in turn, facilitates binding of
elevated concentrations of plasminogen at the cell surface.
Plasminogen is cleaved into plasmin by uPA (urokinase plasminogen
activator), resulting in an increased ability of PDA cells to degrade the
ECM [12]. We targeted surface ENO1 by using a mouse monoclonal
antibody (mAb) that blocks the plasminogen-ENO1 interaction [13].
The anti-human ENO1 mAb inhibited plasminogen-dependent cell
migration through Matrigel in vitro. This invasion requires
simultaneous expression of surface ENO1 and uPAR (receptor for
uPA), as well as expression of uPA. Although uPA and uPAR were not
expressed in PDA cells, in vivo they can be expressed by tumor stromal
cells that are abundantly present in the PDA microenvironment, or up-
regulated in cancer cells by growth factors (such as EGF and HGF) or
cytokines (such as TNF-α, TGF-β) [14-17]. In fact, exposure of ENO1-
expressing PDA cells to TGF-β induced the up-regulation of uPA and
uPAR, which renders the cells sensitive to plasminogen in terms of
increased invasion. In vivo, immune-compromised mice treated with
anti-ENO1 mAb displayed a reduced number of metastasis after xeno-
transplantation of PDA cells compared to control IgG-treated mice
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[13]. These data indicate that ENO1 is involved in the PDA invasion
process, suggesting that interfering with the ENO1-plasminogen
interaction could be useful in inhibiting this invasion. The anti-ENO1
mAb effect is strictly related to this interaction, as demonstrated by in
vitro and in vivo experiments, using PDA cells expressing a triple-
mutated plasminogen binding site of ENO1 (CFPAC-1 TM). These
cells were no longer able to invade in response to plasminogen.
An innovative Adeno Associated Viral Vector (AAVV)-based
therapeutic strategy has been adopted to increase the efficacy of anti-
ENO1 mAb treatment in a metastatic mouse model. This approach
exploited the innovative technology of antibody gene transfer [18-19].
Passive immunization involves the delivery of purified antibodies to
the host with a resulting short-lived immunity, necessitating numerous
inoculations to produce an appreciable effect. By contrast, when the
mAb gene is packaged into an (AAVV) vector and delivered by direct
intramuscular injection, the mAb molecules are endogenously
synthesized and passively distributed to the circulatory system, thus
providing long-term protection. This strategy has been proved to be
successful. After injection of the AAVV expressing anti-ENO1 mAb
(Figure 1 left panel), the presence of the mAb in the mouse sera
progressively increased from 1 to 4 weeks after injection. This
continuous, long-lasting and sustained production of circulating anti-
ENO1 mAb resulted in the observation of a significant decrease in lung
metastases compared to control mice, producing a more pronounced
effect compared to biweekly inoculation of anti-ENO1 mAb (Figure 1
left panel)[13].
Taken together, these findings strongly suggest that blocking the
ENO1/plasminogen interaction through the injection of AAVV-anti-
ENO1 mAb could provide a new therapeutic approach for treating
metastatic PDA patients.
Natural Anti-ENO1 Antibodies Elicited By ENO1
Vaccination
We have also demonstrated that ENO1 is able to induce both
humoral and T cell specific responses in PDA patients [20].
Autoantibodies against ENO1 are detected in more than 60% of PDA
patients, and their presence correlates with a longer survival [7-8]. This
prompted us to propose ENO1 as a therapeutic candidate owing to its
ability to induce an integrated humoral and cellular response. We
developed a DNA vaccination to ENO1 in genetically engineered mice
(GEM) that spontaneously develop autochthonous, lethal pancreatic
cancer [21], and we showed that the vaccine significantly induced a
specific immune response against pancreatic tumors, which efficiently
prolonged mouse survival. We demonstrated that ENO1 DNA
vaccination induced a specific antibody as well as a cellular response in
mice. Notably, DNA vaccination elicited anti-ENO1 IgG binding at the
surface of GEM-derived PDA cells, which killed them by inducing a
complement-dependent cytotoxicity (Figure 1 central panel) [21].
Furthermore, ENO1 DNA vaccination reduced the numbers of
peripheral and intratumoral myeloid-derived suppressor cells (MDSC)
and T-regulatory cells and increased T-helper 1 (Th1) and Th17
responses. Due to the ENO1 cell surface expression on MDSC, and its
enhancement by inflammation, we also investigated if anti-ENO1
antibodies interfered with MDSC invasion in pancreatic tumors [22].
In vitro-generated MDSC treated with anti-ENO1 antibodies were less
able to adhere to pancreatic endothelial cells and invade them or the
Matrigel (Figure1 right panel). In addition, there was significantly less
migration of MDSC treated with anti-ENO1 to the lymph node after
foot-pad injection. Finally, ENO1-vaccinated mice showing anti-ENO1
specific antibodies, displayed a lower percentage of MDSC in the
tumor compared to that evaluated in empty-plasmid vaccinated mice
[22].
Despite ENO1 is found in almost all human tissues [23], the
increased expression of ENO1 and its cell surface localization is a
unique feature of cancer cells. ENO1-specific T cells spared normal
keratinocytes in in vitro cytotoxic assay [20] and no autoimmunity
event nor side effects were detected after DNA-vaccination [21] or
anti-ENO1 mAb treatment [13] in mice. This suggests that both
ENO1-DNA vaccine and anti-ENO1 mAb therapy are safe.
Figure 1: Anti-ENO1 antibody immunotherapy. The plasminogen
receptor ENO1 causes plasminogen to localize to the extracellular
surface, allowing its cleavage into plasmin, catalyzed by uPA bound
to its surface receptor uPAR. Plasmin is a serine protease that
degrades extracellular matrix (ECM) proteins and helps the invasive
process. The anti-ENO1 antibodies, produced using the AAV
construct or elicited by the vaccination, inhibit the binding of
plasminogen to ENO1 or binding to the endothelial cells, blocking
invasion of both tumor cells and MDSC. Anti-ENO1 treated MDSC
also favor Th1 and Th17 cell responses. In addition, anti-ENO1 Abs
mediate complement-dependent cytotoxicity and PDA cell killing.
Conclusion
Metastasis is one of the greatest clinical challenges in modern
oncology; it is, in fact, the disseminated disease that causes the death
of cancer patients. This is especially true for PDA, which is one of the
most aggressive human cancers, due to its high potential of local
invasion and metastasis [5]. Despite many studies, metastasis remains
largely a terra incognita waiting to be explored. Our recent findings
highlight how the anti-ENO1 antibodies inhibit PDA cells, as well as
suppressor immune cells, making the immunotherapy effective (Figure
1). Taken together, these results once again define ENO1 as a
promising molecular and immunological target for the realization of
new personalized therapies for PDA patients.
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